Data from a clinical trial on Dalteparin

Table of Contents


Chronic foot ulcers are a common and severe complication threatening life and limb in patients with diabetes. The data come from a study that aimed to investigate the effect of dalteparin on ulcer outcome in patients with diabetes, peripheral arterial occlusive disease, and chronic foot ulcers. A total of 87 patients were included in a randomized, double-blind, placebo-controlled trial (Kalani et al, 2003). Participants were randomized to treatment with subcutaneous injection of 5,000 units dalteparin or an equivalent volume of physiological saline once daily until ulcer healing or for a maximum of 6 months. The main study outcome was categorical, with five categories, and indicates whether a patient healed with intact skin, the ulcer was "improved", "unchanged", or "impaired" or the patient was amputated.


Variable Explanation
trt Treatment received (Dalteparin or Placebo)
outcome Outcome (6 months of follow-up)

Data download

Format Download
text (csv) dalteparin.csv
rda (for R) dalteparin.rda

Load data into R



Individual-level treatment and outcome data were reconstructed from Table 2 in Kalani et al (2003).


Kalani et al. "Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study." Diabetes care 26.9 (2003): 2575-2580.

Created: 2022-11-11 Fri 10:21